Close
RNS Number : 2087V
Animalcare Group PLC
04 March 2026
 

4 March 2026

 

Animalcare Group plc

("Animalcare", the "Company", or together with its subsidiaries, the "Group")

 

Capital Markets Event: In Good Health

Delivering the next stage of growth, to achieve 2030 revenue and EBITDA ambitions

 

Animalcare Group Plc (AIM: ANCR), the international animal health business, is today hosting a Capital Markets Event to provide greater insight into the three pillars of its growth strategy and outline opportunities to accelerate its growth in the near to medium-term.

 

Over the past five years, Animalcare has undergone a period of transformation, resulting in a rationalised portfolio of higher quality offerings, expanded geographic reach and strengthened balance sheet. More recently, this progress has been accelerated by the earnings accretive acquisition of Randlab, the Australia-based Equine business, and the development of a growing R&D pipeline with transformative growth potential.

 

As part of today's presentations, the Group will introduce new medium-term financial ambitions, including reaching around £150m of revenue with a pathway to 25% EBITDA margin by 2030. Leveraging Animalcare's established and strong commercial platform, these ambitions reflect opportunities to accelerate organic growth in the near to medium-term through investing in activities such as expanding the dental franchise, improving manufacturing efficiency and pursuing selective and accretive M&A.

 

No updates on current trading will be provided during the meeting.

 

Details of the presentation

 

The Capital Markets Event will take place today from 2pm at Stifel's offices in London for pre-registered attendees. Hosted by Animalcare's CEO, Jennifer Winter, and CFO, Chris Brewster, the event will feature presentations from the senior management team, followed by an opportunity to ask questions.  Should you wish to attend, please contact animalcare@almastrategic.com for further details.

 

A copy of the presentation will be made available on the Company's website following the event, with a full replay of the event available in the coming days.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of the Company is Chris Brewster, CFO.

 

For more information, please contact:

Animalcare Group Plc

Jenny Winter, Chief Executive Officer
Chris Brewster, Chief Financial Officer
Media/investor relations

+44 (0)1904 487 687

 

 

communications@animalcaregroup.com



Stifel (Nominated Advisor & Joint Broker)

Ben Maddison

Francis North

Jason Grossman

Tel: +44 (0)20 7710 7600

 



Panmure Liberum (Joint Broker)

Corporate Finance

Emma Earl, Freddy Crossley

Corporate Banking

Rupert Dearden

+44 (0)20 7886 2500



Alma Strategic Communications                                 
Caroline Forde

Kinvara Verdon

Rose Docherty

+44 (0)20 3405 0205

animalcare@almastrategic.com

 

About Animalcare


Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven European countries as well as Australia and New Zealand and exports to approximately 40 countries in Europe and worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.

 

For more information about Animalcare, please visit www.animalcaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZGGFLFDGVZM